"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 0 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 10 | 1 | 11 |
| 2006 | 10 | 0 | 10 |
| 2007 | 11 | 0 | 11 |
| 2008 | 14 | 1 | 15 |
| 2009 | 12 | 0 | 12 |
| 2010 | 6 | 1 | 7 |
| 2011 | 14 | 4 | 18 |
| 2012 | 11 | 0 | 11 |
| 2013 | 21 | 2 | 23 |
| 2014 | 16 | 0 | 16 |
| 2015 | 18 | 0 | 18 |
| 2016 | 23 | 0 | 23 |
| 2017 | 26 | 2 | 28 |
| 2018 | 25 | 2 | 27 |
| 2019 | 27 | 2 | 29 |
| 2020 | 16 | 0 | 16 |
| 2021 | 19 | 1 | 20 |
| 2022 | 18 | 0 | 18 |
| 2023 | 9 | 0 | 9 |
| 2024 | 13 | 1 | 14 |
| 2025 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Aug; 199:96-102.
-
P53-Induced Autophagy Degradation of NKX3-2 Improves Ovarian Cancer Prognosis. Cells. 2025 05 22; 14(11).
-
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025 Mar 18; 25(1):500.
-
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Mar 13; 13(3).
-
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).
-
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. Int J Gynecol Cancer. 2024 Nov; 34(11):1753-1760.
-
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers. Cancer. 2025 Jan 01; 131(1):e35680.
-
Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy. Obstet Gynecol. 2025 Jan 01; 145(1):21-30.
-
NKX3-2 Induces Ovarian Cancer Cell Migration by HDAC6-Mediated Repositioning of Lysosomes and Inhibition of Autophagy. Cells. 2024 Nov 04; 13(21).
-
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.